Rheumatic Diseases (Rheumatism)

01/01/1995 - "Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of treatment for rheumatic diseases. "
02/01/2009 - "The NSAIDs are safe and effective drugs for the treatment of rheumatic diseases. "
09/01/2000 - "Available clinical studies suggest, but do not document, equivalent efficacy of topical over oral NSAIDs in rheumatic diseases."
01/01/2001 - "The efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) in rheumatic diseases depends on their concentrations within the joint. "
04/01/2015 - "Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice."

03/01/2009 - "Tumor necrosis factor (TNF) alpha inhibitors are effective in the treatment of inflammatory rheumatic diseases. "
01/01/2002 - "Preliminary data show that it may be well tolerated and effective in other rheumatic diseases in which there is over production of TNFalpha."
12/01/2014 - "To study the factors associated with withdrawal of the and tumor necrosis factor alpha (anti-TNFα) biologics in the treatment of rheumatic diseases. "
12/01/2011 - "A number of recent studies have indicated that treatment with anti-tumor necrosis factor (TNF) agents in patients with autoimmune/rheumatic diseases carries a similar risk. "
02/01/2010 - "Patients who had taken anti-TNF-alpha for the treatment of rheumatic diseases from January 2002 to May 2008 were included in the study. "

11/01/2002 - "These remarkably positive results have led to the investigation of infliximab treatment for other rheumatic diseases. "
09/01/2011 - "Fifty-eight patients with various rheumatic diseases who received infliximab therapy were enrolled in the trial. "
01/01/2007 - "Short Form Health Survey-36 (SF-36) data from the placebo-controlled phases of 4 studies of infliximab in patients with inflammatory rheumatic diseases (n = 1990) were evaluated. "
12/01/2015 - "To gain clinical experience on the effectiveness and safety of switching from infliximab-Remicade(INX) to infliximab-biosimilar-CT-P13(INB) in patients with established rheumatic disease. "
12/01/2015 - "Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. "

11/01/2014 - "Recent advancements in the treatment for different rheumatic diseases refractory to disease-modifying antirheumatic agents with biologic agents have resulted in remarkable efficacy and tolerability. "
01/01/2007 - "Few disease modifying anti-rheumatic drugs (DMARDs) have been available due to a lack of efficacy of most of the DMARDs used for other rheumatic diseases. "
01/01/2011 - "Among individuals for whom treatment with a new biologic agent or nonbiologic disease-modifying agent in rheumatic disease (DMARD) was being initiated and with registry follow-up at 1 year, VARA and administrative data were used to create a gold standard for the claims-based effectiveness algorithm. "
10/01/2013 - "The increasing use of combination therapies, including disease-modifying antirheumatic drugs (DMARD) and biologicals has improved the outcome for children and adolescents in several rheumatic diseases. "
06/01/2015 - "Under the auspices of the European League Against Rheumatism (EULAR), a study group of investigators representing European biologic DMARD (bDMARD) registers was convened. "

01/01/2004 - "Anticytokine biologics have demonstrated great promise in the treatment of JRA and a variety of other pediatric rheumatic diseases, although at this time the randomized, placebo-controlled data are limited only to etanercept in children with polyarticular JRA. "
02/01/2002 - "This study evaluated the long-term safety and tolerability of open-label use of etanercept when used to treat patients with a variety of systemic rheumatic diseases. "
08/01/2014 - "The introduction of etanercept and other bDMARDs as therapeutic options for patients with autoimmune rheumatic diseases and spondyloarthropathies revolutionized disease management and these agents continue to have a central role in treatment strategies. "
01/01/2012 - "Differences in etanercept levels between good, moderate and European League Against Rheumatism (EULAR) non-responders were assessed after 6 months of therapy. "
11/01/2011 - "[Duration of treatment with etanercept and motives for discontinuation in a cohort of patients with rheumatic disease]."

05/01/2007 - "These antibodies are safe and effective in the long-term therapy of many rheumatic diseases. "
10/01/2013 - "Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases."
10/01/2013 - "Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases"."
04/01/2014 - "In conclusion, our study shows that enthesopathy is more frequent in untreated CD subjects with positive anti-tissue transglutaminase antibodies title, as compared to those on GFD and absence of serum anti-tissue transglutaminase antibodies title. "
01/01/2014 - "The results of our study do not confirm the hypothesis that NTG coexists with elevated blood levels of antibodies, which are a characteristic feature of rheumatic diseases."

09/01/2010 - "Methotrexate has shown efficacy for the control of systemic and articular symptoms and its favourable safety profile appears similar to that seen in other rheumatic diseases, when for this indication. "
03/01/1991 - "Low dose methotrexate has been used effectively for various rheumatic and non-rheumatic diseases. "
12/01/1985 - "This paper will review the findings of the Cooperating Clinics of the American Rheumatism Association, as well as other studies that have investigated the short term efficacy of methotrexate."
07/01/2009 - "A systematic literature search was carried out in MEDLINE, EMBASE, Cochrane Library and American College of Rheumatology/European League Against Rheumatism meeting abstracts, searching for randomised controlled trials evaluating various dosages or routes of administration of methotrexate in RA. "
01/01/1994 - "This parameter was correlated with other clinical observations obtained during a prospective, randomized, placebo-controlled trial of methotrexate, sponsored by the Cooperative Systematic Studies of Rheumatic Diseases consortium. "

04/01/2013 - "The ESPOIR early RA cohort of 813 French patients recruited in 2002-2005 was analyzed to identify patients in remission 6 months after enrollment, according to 2 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria: Boolean ≤ 1 for total tender joint count-28, swollen joint count-28, C-reactive protein, and patient global estimate (PATGL), and Simplified Disease Activity Index (SDAI) ≤ 3.3. "
01/01/2014 - "Both groups demonstrated efficacy through 52 weeks of treatment relative to baseline pretabalumab disease activity based on American College of Rheumatology criteria improvement ≥20%, ≥50% and ≥70%; European League against Rheumatism Responder Index in 28 joints; Disease Activity Score in 28 joints-C-reactive protein; and Health Assessment Questionnaire-Disability Index. "
06/01/2013 - "We compared American College of Rheumatology (ACR) 1981 preliminary definition of remission, European League Against Rheumatism (EULAR) disease activity score of 28 joints - C-reactive protein (DAS28 (3)-CRP) and DAS28 (3)-ESR (erythrocyte sedimentation rate) and newer ACR/EULAR remission criteria from 2011. "
05/15/1976 - "Together with the blood sedimentation rate the exact diagnostics of C-reactive protein gives the possibility of an improved objectivation of the process activity in chronic inflammatory rheumatic diseases."
02/01/2002 - "To determine matrix metalloproteinase-3 (MMP-3) serum levels in patients with rheumatic diseases and to study the relation between MMP-3 and C reactive protein (CRP) levels. "

01/01/2010 - "The main outcome measurements included the Health Assessment Questionnaire (HAQ), the Larsen score, and clinical remission according to the American Rheumatism Association (ARA) criteria. "
12/01/2010 - "Treatment effects were estimated using four outcome measures from the included studies: European League Against Rheumatism (EULAR) and ACR20 response rates and mean improvement in disease activity score-28 (DAS-20) and HAQ. "
11/01/2015 - "The effectiveness of treatment was assessed using the 28-joint Disease Activity Score (DAS28), the Health Assessment Questionnaire (HAQ), measures of remission, the European League Against Rheumatism (EULAR) response during 0-6 months from start of treatment, and survival-on-drug during the first 30 months. "
01/01/2012 - "Subjects (n = 10,319) were selected from the National Data Bank for Rheumatic Diseases, a prospective longitudinal observational US study with semiannual assessments of HAQ, PCS, and MCS. "
09/01/2015 - "Baseline HAQ scores and the HAQ score relationship with medical costs and quality of life were derived from published National Data Bank for Rheumatic Diseases data. "

02/01/2012 - "Although intergroup differences in the percent change of DAS were not statistically significant, ETN + SASP + Bc seemed to be more effective than ETN monotherapy, and the efficacy of ETN + SASP + Bc was comparable to that of ETN + MTX according to the European League Against Rheumatism (EULAR) improvement ratings. "
10/01/2006 - "The groups were also compared for the proportions of patients achieving European League Against Rheumatism (EULAR) good response, Disease Activity Score (DAS)28 remission and treatment terminations. "
01/01/2012 - "Participants included in this study were 208 patients with a rheumatic disease and 975 persons from the Dutch Aging Survey (DAS). "
09/01/2005 - "The DAS-based European League Against Rheumatism (EULAR) response criteria were developed to measure individual response in clinical trials. "
05/01/2014 - "Response to the treatment was evaluated at 3, 6, and 12 months of follow-up as the change in the Disease Activity Score (DAS) 28 from baseline and as the response by the European League Against Rheumatism (EULAR) criteria. "

01/01/2015 - "The introduction of biological therapies has significantly improved the outcome of inflammatory rheumatic diseases. "
05/01/2015 - "The treatment of autoimmune rheumatic diseases has gradually improved over the last half century, which has been expanded with the contribution of biological therapies or immunobiopharmaceuticals. "
11/01/2009 - "The morbidity and mortality of patients with rheumatic diseases has improved considerably following the use of biologic therapies. "
09/01/2008 - "The prognosis of patients with rheumatic diseases has improved considerably following the use of biological therapies. "
05/01/2015 - "Study participants were a cohort from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (BIOBADABRASIL) between 2008 and 2012. "

07/01/2014 - "The purpose of this preliminary study was to investigate the short-term efficacy, safety, and injectable volume of HA in the treatment of enthesopathies. "
04/15/2005 - "Consecutive patients with chronic rheumatic diseases admitted to the hospital for local CS injections of painful ankle, hindfoot, or midfoot were enrolled in this study. "
05/01/2013 - "Autologous blood and platelet-rich plasma injections for enthesopathy of the extensor carpi radialis brevis origin."
08/01/2011 - "Joint and soft tissue injections are routinely performed in daily rheumatology practice to establish the diagnosis or as part of the treatment in patients suffering from rheumatic diseases. "
08/01/2011 - "[Ultrasound-guided joint injections in patients with rheumatic diseases]."

04/01/2001 - "Study of two plants used in traditional medicine in Zimbabwe for skin problems and rheumatism: Dioscorea sylvatica and Urginea altissima."
08/01/2014 - "(Lamiaceae) is extensively used in traditional medicine in major parts of India for several medicinal purposes, including their use in rheumatism. "
01/01/2014 - "In Mexican traditional medicine, the seeds of Byrsonima crassifolia have been used in the treatment of diabetes, rheumatism and for wound healing. "
05/20/2013 - "Sphaeralcea angustifolia Cavanilles & Don (Malvaceae), known in Mexico as "Vara de San José", is used in Mexican Traditional Medicine as an anti-inflammatory and, more specifically, for treating rheumatism. "
05/01/2013 - "The root and stem of this plant is a folk medicine known to have the actions of relieving rheumatism and cold and subsiding swelling and pains. "

12/01/2000 - "Data from all transplanted patients are being collated in a centralized register by the European Group for Blood and Marrow Transplantation (EBMT) and the European League against Rheumatism (EULAR) to enable effective evaluation of the safety and efficacy of this promising technique. "
01/01/2004 - "The European Group for Blood and Marrow Transplantation (EBMT) and The European League Against Rheumatism (EULAR) have analysed their collective phase I and II studies and found a remission rate (based on a reduction of the SLEDAI to < 3) in 66%, one-third of whom later relapsed to some degree. "
12/01/2001 - "Based on a concept statement issued in 1995, two European societies, the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) began collecting phase I/II trial data in an international collaborative network. "
09/01/2009 - "While PSIs are widely used in transplantation, there are few reports of PSI usage in the treatment of autoimmune rheumatic diseases. "
11/01/2007 - "The changes of both clinical manifestations and immunologic indexes were observed before and after transplantation with long term following up at specialty clinic of rheumatism. "

11/01/1981 - "[Quantitative relation between the efficacy of mud therapy and weather changes in patients with rheumatic diseases]."
01/01/2015 - "The mud-bath therapy is a spa treatment that induces benefic effects in chronic rheumatic diseases. "
01/01/2003 - "[Fangotherapy in chronic degenerative rheumatic diseases]."
08/01/2002 - "Mud pack therapy is an alternative mode of treatment for rheumatic diseases. "
11/01/1993 - "[Effects of thermal balneo-fangotherapy on extra-articular rheumatic diseases in relation to sports activity]."